mRNA vaccines once again open up new battlefields to challenge latent viruses

mRNA technology has achieved great success in the development of new crown vaccines, which has also inspired the application of mRNA technology in the development of other infectious disease vaccines

Pfizer and BioNTech collaborate again to develop mRNA shingles vaccine

Today, Pfizer and BioNTech announced that they have entered into a new research and development collaboration to jointly develop an mRNA vaccine to prevent shingles

Shingles is a chronic infection of the varicella-zoster virus.

Under the agreement, the parties will utilize the unique antigen technology discovered by Pfizer scientists and BioNTech's mRNA technology platform

"Pfizer and BioNTech have jointly developed the world's first mRNA vaccine, providing a well-tolerated and effective tool in the fight against

Moderna's Epstein-Barr virus vaccine enters clinic

Moderna announced that the first patient has been dosed in a Phase 1 clinical trial of the company's Epstein-Barr virus (EBV) vaccine candidate, mRNA-1189

EBV is a common viral infection that is spread through bodily fluids, usually in early childhood or during adolescence

Moderna's vaccine candidate, mRNA-1189, is designed to prevent EBV-challenged infectious mononucleosis and potentially prevent EBV infection

The Phase 1 clinical trial is expected to enroll approximately 270 adult volunteers aged 18-30 and will primarily assess the safety and tolerability of mRNA-1189

References:

[1] Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine.

[2] MODERNA ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 1 STUDY OF ITS MRNA EPSTEIN-BARR VIRUS (EBV) VACCINE.

(Original abridged)